ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD


Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) today announced it has reached a manufacturing agreement with Famar Health Care Services Madrid SAU (“Famar”), a European provider of pharmaceutical manufacturing and development services. Famar will deliver clinical trial material of the newly developed eye-drop formulation of laqui­nimod.

View original post here:
ACTIVE BIOTECH ENTERS INTO A MANUFACTURING AGREEMENT WITH FAMAR HEALTH CARE SERVICES FOR NEW FORMULATION OF LAQUINIMOD

Related Posts